Is PIII or XGN more profitable?

P3 Health Partners has a net margin of -6.55% compared to Exagen's net margin of -26.61%. P3 Health Partners' return on equity of 0.00% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets P3 Health Partners -6.55% N/A -16.40% Exagen -26.61% -104.46% -28.93%

Is LFMD or PIII more profitable?

LifeMD has a net margin of 0.10% compared to P3 Health Partners' net margin of -6.55%. P3 Health Partners' return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 0.10% -168.23% -31.27% P3 Health Partners -6.55% N/A -16.40%

Do analysts recommend JYNT or PIII?

P3 Health Partners has a consensus price target of $17.00, suggesting a potential upside of 101.66%. Given P3 Health Partners' higher probable upside, analysts plainly believe P3 Health Partners is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 P3 Health Partners 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is JYNT or PIII more profitable?

Joint has a net margin of 6.49% compared to P3 Health Partners' net margin of -6.55%. Joint's return on equity of 12.02% beat P3 Health Partners' return on equity. Company Net Margins Return on Equity Return on Assets Joint 6.49% 12.02% 3.47% P3 Health Partners -6.55% N/A -16.40%

Is PARK or PIII more profitable?

Park Dental Partners has a net margin of 0.00% compared to P3 Health Partners' net margin of -6.55%. Company Net Margins Return on Equity Return on Assets Park Dental Partners N/A N/A N/A P3 Health Partners -6.55% N/A -16.40%

P3 Health Partners (PIII) Competitors

$8.43 +0.07 (+0.84%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$8.11 -0.32 (-3.80%)

As of 09/11/2026 07:30 PM Eastern

Compare

PIII vs. INFU, XGN, LFMD, JYNT, and PARK

Should you buy P3 Health Partners stock or one of its competitors? P3 Health Partners's main competitors and comparable companies include InfuSystem (INFU), Exagen (XGN), LifeMD (LFMD), Joint (JYNT), and Park Dental Partners (PARK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does P3 Health Partners compare to InfuSystem?

P3 Health Partners (NASDAQ:PIII) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, P3 Health Partners and P3 Health Partners both had 1 articles in the media. InfuSystem's average media sentiment score of 1.63 beat P3 Health Partners' score of 0.93 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Overall Sentiment
P3 Health Partners	Positive
InfuSystem	Very Positive

InfuSystem has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.04	-$147.95M	-$33.00	N/A
InfuSystem	$143.34M	1.71	$870K	$0.41	29.63

InfuSystem has a net margin of 1.12% compared to P3 Health Partners' net margin of -6.55%. InfuSystem's return on equity of 2.78% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
InfuSystem	1.12%	2.78%	1.41%

P3 Health Partners currently has a consensus target price of $17.00, suggesting a potential upside of 101.66%. InfuSystem has a consensus target price of $16.67, suggesting a potential upside of 37.17%. Given P3 Health Partners' higher probable upside, equities analysts plainly believe P3 Health Partners is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

P3 Health Partners has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by insiders. Comparatively, 10.8% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

InfuSystem beats P3 Health Partners on 11 of the 15 factors compared between the two stocks.

How does P3 Health Partners compare to Exagen?

P3 Health Partners (NASDAQ:PIII) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

In the previous week, Exagen had 4 more articles in the media than P3 Health Partners. MarketBeat recorded 5 mentions for Exagen and 1 mentions for P3 Health Partners. Exagen's average media sentiment score of 1.18 beat P3 Health Partners' score of 0.93 indicating that Exagen is being referred to more favorably in the news media.

Company	Overall Sentiment
P3 Health Partners	Positive
Exagen	Positive

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by insiders. Comparatively, 10.4% of Exagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

P3 Health Partners has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, Exagen has a beta of 2.1, meaning that its stock price is 110% more volatile than the broader market.

P3 Health Partners presently has a consensus price target of $17.00, indicating a potential upside of 101.66%. Exagen has a consensus price target of $9.63, indicating a potential upside of 36.91%. Given P3 Health Partners' higher probable upside, research analysts clearly believe P3 Health Partners is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

P3 Health Partners has a net margin of -6.55% compared to Exagen's net margin of -26.61%. P3 Health Partners' return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
Exagen	-26.61%	-104.46%	-28.93%

Exagen has lower revenue, but higher earnings than P3 Health Partners. Exagen is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46B	0.04	-$147.95M	-$33.00	N/A
Exagen	$66.57M	2.56	-$19.95M	-$0.81	N/A

Summary

Exagen beats P3 Health Partners on 10 of the 17 factors compared between the two stocks.

How does P3 Health Partners compare to LifeMD?

LifeMD (NASDAQ:LFMD) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

LifeMD has a net margin of 0.10% compared to P3 Health Partners' net margin of -6.55%. P3 Health Partners' return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-168.23%	-31.27%
P3 Health Partners	-6.55%	N/A	-16.40%

In the previous week, LifeMD had 4 more articles in the media than P3 Health Partners. MarketBeat recorded 5 mentions for LifeMD and 1 mentions for P3 Health Partners. P3 Health Partners' average media sentiment score of 0.93 beat LifeMD's score of 0.90 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
LifeMD	Positive
P3 Health Partners	Positive

LifeMD has higher earnings, but lower revenue than P3 Health Partners. LifeMD is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.76	$14.35M	-$0.05	N/A
P3 Health Partners	$1.46B	0.04	-$147.95M	-$33.00	N/A

LifeMD has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

LifeMD currently has a consensus price target of $7.57, indicating a potential upside of 148.24%. P3 Health Partners has a consensus price target of $17.00, indicating a potential upside of 101.66%. Given LifeMD's stronger consensus rating and higher probable upside, equities research analysts clearly believe LifeMD is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

LifeMD beats P3 Health Partners on 11 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to Joint?

Joint (NASDAQ:JYNT) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

In the previous week, Joint and Joint both had 1 articles in the media. Joint's average media sentiment score of 1.81 beat P3 Health Partners' score of 0.93 indicating that Joint is being referred to more favorably in the media.

Company	Overall Sentiment
Joint	Very Positive
P3 Health Partners	Positive

Joint has a net margin of 6.49% compared to P3 Health Partners' net margin of -6.55%. Joint's return on equity of 12.02% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
P3 Health Partners	-6.55%	N/A	-16.40%

Joint has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

P3 Health Partners has a consensus price target of $17.00, suggesting a potential upside of 101.66%. Given P3 Health Partners' higher probable upside, analysts plainly believe P3 Health Partners is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

76.9% of Joint shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 30.2% of Joint shares are held by insiders. Comparatively, 10.9% of P3 Health Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Joint has higher earnings, but lower revenue than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.02	$2.91M	$0.27	29.07
P3 Health Partners	$1.46B	0.04	-$147.95M	-$33.00	N/A

Summary

Joint beats P3 Health Partners on 10 of the 14 factors compared between the two stocks.

How does P3 Health Partners compare to Park Dental Partners?

Park Dental Partners (NASDAQ:PARK) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Park Dental Partners has a net margin of 0.00% compared to P3 Health Partners' net margin of -6.55%.

Company	Net Margins	Return on Equity	Return on Assets
Park Dental Partners	N/A	N/A	N/A
P3 Health Partners	-6.55%	N/A	-16.40%

7.8% of P3 Health Partners shares are owned by institutional investors. 10.6% of Park Dental Partners shares are owned by company insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Park Dental Partners has higher earnings, but lower revenue than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Park Dental Partners	$244.49M	0.40	-$360K	$1.05	19.61
P3 Health Partners	$1.46B	0.04	-$147.95M	-$33.00	N/A

Park Dental Partners currently has a consensus price target of $28.50, suggesting a potential upside of 38.42%. P3 Health Partners has a consensus price target of $17.00, suggesting a potential upside of 101.66%. Given P3 Health Partners' higher probable upside, analysts clearly believe P3 Health Partners is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Park Dental Partners and Park Dental Partners both had 1 articles in the media. Park Dental Partners' average media sentiment score of 1.89 beat P3 Health Partners' score of 0.93 indicating that Park Dental Partners is being referred to more favorably in the media.

Company	Overall Sentiment
Park Dental Partners	Very Positive
P3 Health Partners	Positive

Summary

Park Dental Partners beats P3 Health Partners on 9 of the 13 factors compared between the two stocks.

Get P3 Health Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PIII vs. The Competition

Export

Metric	P3 Health Partners	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$61.21M	$9.84B	$7.16B	$12.85B
Dividend Yield	N/A	2.61%	2.57%	11.17%
P/E Ratio	-0.26	33.53	274.94	25.36
Price / Sales	0.04	4.89	685.45	116.82
Price / Cash	N/A	125.15	76.65	51.52
Price / Book	-0.39	5.29	10.33	6.20
Net Income	-$147.95M	$313.25M	$3.50B	$358.50M
7 Day Performance	-9.84%	-1.26%	-3.32%	-2.35%
1 Month Performance	-23.01%	-1.53%	-0.53%	-3.23%
1 Year Performance	-1.98%	58.44%	23.51%	8.79%

P3 Health Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PIII P3 Health Partners	2.568 of 5 stars	$8.43 +0.8%	$17.00 +101.7%	-2.0%	$61.21M	$1.46B	N/A	500
INFU InfuSystem	3.8606 of 5 stars	$12.10 -0.4%	$16.67 +37.7%	+21.6%	$244.20M	$143.34M	201.70	410	Positive News
XGN Exagen	4.3138 of 5 stars	$7.12 -3.0%	$9.63 +35.2%	-27.8%	$177.81M	$66.57M	N/A	220	News Coverage Positive News Analyst Forecast
LFMD LifeMD	2.4614 of 5 stars	$3.10 +0.3%	$7.57 +144.2%	-47.4%	$148.94M	$194.05M	N/A	230	Positive News Analyst Forecast
JYNT Joint	2.7784 of 5 stars	$8.36 -0.9%	N/A	-22.0%	$119.37M	$54.90M	30.96	320

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PIII) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

P3 Health Partners (PIII) Competitors

PIII vs. INFU, XGN, LFMD, JYNT, and PARK

How does P3 Health Partners compare to InfuSystem?

Summary

How does P3 Health Partners compare to Exagen?

Summary

How does P3 Health Partners compare to LifeMD?

Summary

How does P3 Health Partners compare to Joint?

Summary

How does P3 Health Partners compare to Park Dental Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIII vs. The Competition

P3 Health Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

P3 Health Partners (PIII) Competitors

PIII vs. INFU, XGN, LFMD, JYNT, and PARK

How does P3 Health Partners compare to InfuSystem?

Does the media refer more to PIII or INFU?

Which has better earnings and valuation, PIII or INFU?

Is PIII or INFU more profitable?

Do analysts rate PIII or INFU?

Which has more volatility & risk, PIII or INFU?

Do insiders & institutionals hold more shares of PIII or INFU?

Summary

How does P3 Health Partners compare to Exagen?

Does the media prefer PIII or XGN?

Do institutionals and insiders hold more shares of PIII or XGN?

Which has more volatility & risk, PIII or XGN?

Do analysts rate PIII or XGN?

Is PIII or XGN more profitable?

Which has better earnings and valuation, PIII or XGN?

Summary

How does P3 Health Partners compare to LifeMD?

Is LFMD or PIII more profitable?

Does the media prefer LFMD or PIII?

Which has stronger valuation & earnings, LFMD or PIII?

Which has more volatility & risk, LFMD or PIII?

Do institutionals and insiders believe in LFMD or PIII?

Do analysts recommend LFMD or PIII?

Summary

How does P3 Health Partners compare to Joint?

Does the media favor JYNT or PIII?

Is JYNT or PIII more profitable?

Which has more volatility & risk, JYNT or PIII?

Do analysts recommend JYNT or PIII?

Do institutionals and insiders have more ownership in JYNT or PIII?

Which has preferable earnings and valuation, JYNT or PIII?

Summary

How does P3 Health Partners compare to Park Dental Partners?

Is PARK or PIII more profitable?

Do institutionals & insiders hold more shares of PARK or PIII?

Which has better earnings & valuation, PARK or PIII?

Do analysts rate PARK or PIII?

Does the media prefer PARK or PIII?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PIII vs. The Competition

P3 Health Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools